Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study

BACKGROUND: Glycopyrronium is a once-daily (od) long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The GLOW7 study evaluated the efficacy and safety of od glycopyrronium 50 μg in predominantly Chinese patients with moderate-to-severe COPD...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chen, Sun, Tieying, Huang, Yijiang, Humphries, Michael, Bai, Lingyan, Li, Lilly, Wang, Qian, Kho, Pearl, Firth, Roz, D’Andrea, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293291/
https://www.ncbi.nlm.nih.gov/pubmed/25609940
http://dx.doi.org/10.2147/COPD.S72650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293291/
https://www.ncbi.nlm.nih.gov/pubmed/25609940
http://dx.doi.org/10.2147/COPD.S72650

Ejemplares similares